Global Top 25 Companies in AI in Diabetic Retinopathy Market by Transpire Insight

By Transpire Insight

---

Description

According to a research report published by Transpire Insight, The Global AI in Diabetic Retinopathy Market Size is projected to Grow from USD 153.6 Million in 2025 to USD 835.9 Million by 2035, at a CAGR of 34.5% during the forecast period 2026-2035. The growth in the market is attributed to the rising prevalence of diabetes across the globe, higher demand for early diagnosis of retinal diseases, lack of ophthalmologists, and growing adoption of AI technology in diagnostics. The growth is further fueled by technological innovations in the field of deep learning algorithms, approval of autonomous AI diagnostic tools, increased development of telemedicine infrastructure, and investment in digital health. In addition, the integration of AI technology in cloud-based ophthalmic software, improvements in retinal imaging technology, and government efforts to promote diabetic screening programs offer huge potential.

Introduction

AI in Diabetic Retinopathy Market is defined as software, imaging systems, algorithms, and decision support solutions powered by artificial intelligence technology that can be used for detection, classification, and monitoring of diabetic retinopathy through analysis of retinal images. This is done through the use of machine learning and deep learning algorithms which analyze fundus photographs and optical coherence tomography (OCT) images. This technology finds applications in hospitals, ophthalmology clinics, diagnostic imaging centers, primary care facilities, and teleophthalmology service providers.

Recent Development News

• July 2026: Got approval from FDA 510(k) for the iPredict-DR, an artificial intelligence-based tool to detect mild diabetic retinopathy from retinal fundus pictures.

• July 2026: FDA allowed extended interval of EYLEA HD treatment for diabetic macular edema, which will help reduce the hassle of treatment of those patients detected through automated systems.

Stay Ahead of Emerging Opportunities with Expert Market Insights by Transpire Insight

The insights that have been shared through this blog are based on intensive market research carried out by Transpire Insight, an advisor that works with many global organizations. Thanks to the analysis of extensive data, forecasts made by our specialists, and industry intelligence, our reports allow clients to find strategic growth opportunities in dynamically developing industries. For all those who would like to get more detailed information regarding market segmentation, competitive analysis, regional outlooks, and future investment tendencies, there is no doubt that our full report will be of great value.

Download the exclusive AI in Diabetic Retinopathy Market sample report today to uncover expert insights, emerging trends, and the opportunities defining the future of the industry.

AI in Diabetic Retinopathy Market Size & Statistics

• Market Size of the AI in Diabetic Retinopathy Market was projected to be USD 153.6 Million in 2025. 
• The Market Size is Expected to Grow at a CAGR of 34.5% from 2026 to 2035. 
• The Market Size of the Global AI in Diabetic Retinopathy Market Size is expected to be USD 835.9 Million in 2035.
• The North American region is expected to be the largest consumer in the forecast period, contributing approximately 42% to the AI in Diabetic Retinopathy Market, owing to its well-developed healthcare system, early adoption of AI diagnostic tools, positive regulatory support, and substantial investment in digital ophthalmology.
• The Asia Pacific region is anticipated to witness the fastest growth in the forecast period, contributing approximately 35% to the growth in the AI in Diabetic Retinopathy Market, due to the fast-growing diabetic population, growing number of teleophthalmology projects, government diabetic screening programs, and adoption of AI-based healthcare solutions.

Regional Growth and Demand Analysis by Transpire Insight:

The North American region is expected to be the largest consumer in the forecast period, contributing approximately 42% to the AI in Diabetic Retinopathy Market, owing to its well-developed healthcare system, early adoption of AI diagnostic tools, positive regulatory support, and substantial investment in digital ophthalmology.

The Asia Pacific region is anticipated to witness the fastest growth in the forecast period, contributing approximately 35% to the growth in the AI in Diabetic Retinopathy Market, due to the fast-growing diabetic population, growing number of teleophthalmology projects, government diabetic screening programs, and adoption of AI-based healthcare solutions.

Top 15 Trends in the AI in Diabetic Retinopathy Market

1. Growing Adoption of Autonomous AI-Based Retinal Screening 
2. Expansion of Deep Learning Algorithms for Retinal Image Analysis 
3. Increasing Integration of AI with Teleophthalmology Platforms 
4. Rising Demand for Cloud-Based Ophthalmic Diagnostic Solutions 
5. Advancements in AI-Powered Optical Coherence Tomography (OCT) Analysis 
6. Growing Use of AI for Early Diabetic Retinopathy Detection 
7. Expansion of AI-Enabled Portable Retinal Imaging Devices 
8. Increasing Adoption of AI in Primary Care Eye Screening 
9. Development of Real-Time Clinical Decision Support Systems 
10. Growing Regulatory Approvals for AI Diagnostic Software 
11. Expansion of AI-Driven Population-Based Screening Programs 
12. Increasing Investment in Explainable AI for Healthcare 
13. Growing Collaboration Between AI Companies and Healthcare Providers 
14. Advancements in Multimodal Ophthalmic AI Platforms 
15. Rising Adoption of AI for Predictive Disease Progression Analysis 

Proceed to Checkout to purchase the exclusive AI in Diabetic Retinopathy Market report and gain instant access to in-depth market intelligence, strategic analysis, and future growth opportunities.

1. Growing Adoption of Autonomous AI-Based Retinal Screening

Independent AI screening devices are gradually being introduced to screen for diabetic retinopathy without necessarily requiring a follow-up with a specialist at the time of diagnosis. This is due to several reasons, including regulatory clearance, quicker diagnoses, reduction in the workload of ophthalmologists, increased screening coverage, and improved diagnostic accuracy.

2. Expansion of Deep Learning Algorithms for Retinal Image Analysis

The advent of deep learning technology is helping enhance the precision in interpreting retinal images because of the detection of minute pathologies related to diabetic retinopathy. There are many benefits driving the use of deep learning technology in diabetic retinopathy, including improved diagnosis precision and algorithm enhancement.

3. Increasing Integration of AI with Teleophthalmology Platforms

AI-based diagnostic technologies are being used together with teleophthalmology services by healthcare professionals to provide diabetic eye screenings in under-serviced and rural areas. Faster remote diagnosis, better access to specialists, less travel for patients, efficient referral management, scalable screening programs, and increased healthcare accessibility are boosting market growth.

4. Rising Demand for Cloud-Based Ophthalmic Diagnostic Solutions

AI systems in the cloud environment are making it possible for health practitioners to analyze retinal images, manage patients’ data, and assist in clinical decision-making. Centralization of data management, automated software update, workflow efficiency, scalability, security, and interoperability are contributing to this growing trend.

5. Advancements in AI-Powered Optical Coherence Tomography (OCT) Analysis

There is increased utilization of artificial intelligence within OCT imaging systems, as a means of enhancing the detection of retinal problems and tracking disease development. Some of the factors that are promoting the adoption include automated image analysis, early detection of retinal damage, and better treatment planning.

6. Growing Use of AI for Early Diabetic Retinopathy Detection

Early detection has become a very important issue since artificial intelligence can detect diabetic retinopathy at an early stage when there is no visual impairment yet. Preventive care, improved screening efficiency, prompt clinical management, slowed down disease progression, better outcomes for patients, and increased use in national diabetic screening programs keep reinforcing this tendency.

Top 25 Companies Leading the AI in Diabetic Retinopathy Market

1. Digital Diagnostics Inc.
2. Eyenuk Inc.
3. Topcon Corporation
4. Canon Medical Systems Corporation
5. NIDEK Co., Ltd.
6. Optomed Plc
7. ZEISS Group
8. F. Hoffmann-La Roche Ltd.
9. Siemens Healthineers AG
10. Google Health
11. IBM Corporation
12. Microsoft Corporation
13. Medtronic plc
14. Remidio Innovative Solutions Pvt. Ltd.
15. Visulytix Ltd.
16. AEYE Health
17. iHealthScreen Inc.
18. Retmarker S.A.
19. IDx Technologies
20. HealPros LLC
21. Intelerad Medical Systems
22. Lunit Inc.
23. NetraDyne Inc.
24. Alibaba Health Information Technology Limited
25. Tencent Healthcare

Customize the exclusive AI in Diabetic Retinopathy Market report today to receive tailored insights, country-specific analysis, and business-focused market intelligence.

1. Digital Diagnostics Inc.

Digital Diagnostics is a healthcare AI company specializing in autonomous artificial intelligence systems for disease detection, particularly diabetic retinopathy.

Founded:2010 | Headquarters: Coralville, Iowa, USA

Why It Ranks: Pioneer in FDA-authorized autonomous AI diagnostic solutions for diabetic retinopathy.

Regional Dominance: Strong presence across North America.

Product Line: Autonomous AI Diagnostic Software, Retinal Screening Solutions, and Digital Ophthalmology Platforms.

Recent Development: Expanded deployment of autonomous AI retinal screening systems across healthcare networks.

2. Eyenuk Inc.

Eyenuk develops AI-powered ophthalmology software for automated screening and detection of diabetic retinopathy and other retinal diseases.

Founded:2010 | Headquarters: Los Angeles, California, USA

Why It Ranks: Leading provider of AI-enabled diabetic retinopathy screening technology.

Regional Dominance: Strong presence across North America, Europe, and Asia-Pacific.

Product Line: EyeArt AI Screening System, Retinal Image Analysis Software, and Ophthalmic AI Solutions.

Recent Development: Expanded regulatory approvals for AI-based diabetic retinopathy screening.

3. Topcon Corporation

Topcon manufactures advanced ophthalmic imaging equipment and healthcare technologies for eye disease diagnosis.

Founded:1932 | Headquarters: Tokyo, Japan

Why It Ranks: Global leader in retinal imaging systems integrated with AI diagnostics.

Regional Dominance: Strong presence across Asia-Pacific, Europe, and North America.

Product Line: Fundus Cameras, OCT Systems, Retinal Imaging Devices, and Digital Eye Care Solutions.

Recent Development: Enhanced AI integration across retinal imaging platforms.

4. Canon Medical Systems Corporation

Canon Medical Systems develops diagnostic imaging technologies, including ophthalmic imaging and AI-assisted healthcare solutions.

Founded:1930 | Headquarters: Otawara, Japan

Why It Ranks: Strong expertise in advanced diagnostic imaging technologies.

Regional Dominance: Strong presence across Asia-Pacific, Europe, and North America.

Product Line: Ophthalmic Imaging Systems, OCT Devices, Medical Imaging Equipment, and AI Healthcare Solutions.

Recent Development: Expanded AI-supported ophthalmology imaging capabilities.

5. NIDEK Co., Ltd.

NIDEK develops ophthalmic diagnostic instruments, surgical equipment, and retinal imaging systems.

Founded:1971 | Headquarters: Gamagori, Japan

Why It Ranks: Leading supplier of ophthalmic diagnostic technologies.

Regional Dominance: Strong presence across Asia-Pacific, Europe, and North America.

Product Line: Fundus Cameras, OCT Systems, Ophthalmic Diagnostic Equipment, and Vision Care Devices.

Recent Development: Introduced advanced retinal imaging technologies supporting AI integration.

6. Optomed Plc

Optomed develops portable retinal imaging devices and AI-based screening solutions for eye disease detection.

Founded:2004 | Headquarters: Oulu, Finland

Why It Ranks: Recognized innovator in handheld retinal imaging and AI diagnostics.

Regional Dominance: Strong presence across Europe and North America.

Product Line: Handheld Fundus Cameras, AI Retinal Screening Systems, and Digital Ophthalmology Solutions.

Recent Development: Expanded portable AI-enabled retinal screening deployments.

7. ZEISS Group

ZEISS is a global technology company specializing in optics, medical technology, industrial measurement, and semiconductor manufacturing.

Founded:1846 | Headquarters: Oberkochen, Germany

Why It Ranks: Global leader in ophthalmic imaging and digital eye care technologies.

Regional Dominance: Strong presence across Europe, North America, and Asia-Pacific.

Product Line: OCT Systems, Fundus Imaging Devices, Surgical Microscopes, and AI Ophthalmology Platforms.

Recent Development: Strengthened AI-powered ophthalmic imaging portfolio.

8. F. Hoffmann-La Roche Ltd.

Roche is a multinational healthcare company specializing in pharmaceuticals and diagnostics.

Founded:1896 | Headquarters: Basel, Switzerland

Why It Ranks: Strong diagnostic expertise supporting AI-enabled disease detection.

Regional Dominance: Strong presence across Europe, North America, and Asia-Pacific.

Product Line: Diagnostic Solutions, Digital Pathology, Molecular Diagnostics, and Healthcare AI Platforms.

Recent Development: Expanded digital diagnostics capabilities through AI collaborations.

9. Siemens Healthineers AG

Siemens Healthineers develops medical imaging systems, laboratory diagnostics, and AI-enabled healthcare technologies.

Founded:2017(as independent company) | Headquarters: Erlangen, Germany

Why It Ranks: Leading provider of AI-powered diagnostic imaging solutions.

Regional Dominance: Strong presence across Europe, North America, and Asia-Pacific.

Product Line: Medical Imaging Systems, AI Diagnostic Platforms, Laboratory Diagnostics, and Digital Healthcare Solutions.

Recent Development: Expanded AI-assisted imaging solutions for ophthalmology.

10. Google Health

Google Health develops artificial intelligence technologies that improve disease detection, medical imaging analysis, and clinical decision support.

Founded:2018 | Headquarters: Mountain View, California, USA

Why It Ranks: Pioneer in applying deep learning algorithms to retinal disease detection.

Regional Dominance: Strong presence across North America and global research collaborations.

Product Line: AI Healthcare Algorithms, Medical Imaging AI, Clinical Decision Support, and Digital Health Technologies.

Recent Development: Continued advancement of AI models for diabetic retinopathy screening and ophthalmic diagnostics.

Schedule a meeting with our market experts to discuss the exclusive AI in Diabetic Retinopathy Market report and identify the best research solution for your organization.

Conclusion

AI in Diabetic Retinopathy Market is witnessing high growth because healthcare institutions are relying heavily on artificial intelligence to increase the accuracy of diabetic eye disease detection. The growing prevalence of diabetes across the globe, scarcity of ophthalmologists, and need for efficient and timely screenings have fueled the adoption of retinal imaging and diagnostics powered by artificial intelligence technology. Innovations in deep learning, cloud computing, teleophthalmology, and advanced diagnostic software will lead to efficient screening and improved patient outcomes. Companies like Digital Diagnostics Inc., Eyenuk Inc., Topcon Corporation, Canon Medical Systems Corporation, NIDEK Co., Ltd., Optomed Plc, ZEISS Group, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, and Google Health are constantly innovating through product development, approval of regulatory authorities, and collaborations. As artificial intelligence continues to be integrated into ophthalmological practices and diabetic screening programs, the AI in Diabetic Retinopathy Market is set for strong long-term growth in the coming years.